Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L
Nov
26
2024
On demand

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Tuesday 11:30 IST / 14:00 AWST / 15:00 KST / 15:00 JST / 17:00 AEDT / 19:00 NZDT
Sponsor
Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Viral vector-based gene therapies have made great progress to date, and several products that treat rare genetic diseases are commercially available. The clinical pipeline is growing steadily, with the focus turning to more prevalent indications targeted using primarily recombinant AAVs (rAAVs). Rising demand for rAAV quantities is driving the need for robust process development and large-scale manufacturing capabilities.

In this webinar, OBiO Technology will highlight their process development strategies to scale up a transient transfection-based AAV production process from 15 to 1,000L in a single-use, stirred-tank bioreactor.

  • How to achieve large-scale cultivation of HEK293 suspension cells
  • Methods to perform effective triple-plasmid transient transfection at large scale
  • Strategies for scaling up an upstream process to 1,000L
Qingrui You
Qingrui You
Vice President at Obio Technology Shanghai

Dr. You is the Vice President of OBiO Technology in Shanghai. Focusing on gene and cell therapy, he leads a team working on Chemistry, Manufacturing and Controls (CMC) segment in support of the Investigational New Drug Application (IND) project.

Dr. You has over 15 years of experience in biologics development, process development and technical transfer. Prior to OBiO Technology,Dr. You served as senior PD scientist in General Electric (GE) China Technology Center. His experience covers a wide range of products such as DNA plasmids, subunit vaccines, antibodies, and virus-vectored products.

Peiqing Zhang
Peiqing Zhang
Strategic Technology Partnership Leader, Genomic Medicine Asia at Cytiva

As a member of the Chief Scientific Officer’s team, Peiqing leads genomic medicine technology management and partnership programs in Asia.

With 18 years of relevant experience, Peiqing strives to connect the dots for therapeutic developers to achieve efficient and GMP-compatible manufacturing platforms. He earned his PhD from the National University of Singapore (NUS) and developed his technical expertise and leadership skills in academic institutions, start-up biotechs, and big pharma, including the Agency for Science, Technology and Research (A*STAR) and Novartis. Through his professional journey in these different organizations, he has led and contributed to product characterization platforms and drug development programs. Peiqing is a newshound and always wishes for more time to read many innovative scientific papers that are published each day.